Abstract
This chapter will describe methods that may be used to deliver agents to HIV-infected cells. These materials may be used for therapeutic or experimental purposes. There are several general approaches to delivering compounds to human immunodeficiency cells (HIV)-infected cells. All cells may be exposed to materials that only have an effect or become activated in HIV-infected cells. Examples include drugs that are specific for HIV-encoded enzymes, such as reverse transcriptase or protease, or genes that are expressed under the control of the HIV-LTR. Lack of specificity is a major limitation to this approach; for example, reverse transcriptase inhibitors also inhibit cellular DNA polymerases and cellular transcription factors clan initiate low-level-transcription off the HIV-LTR, even in the absence of tat. The alternative approach, which is the subject of this chapter, is to target the materials specifically to the infected cells. We have used monoclonal antibodies (MAbs) to deliver toxins to HIV-infected cells, but others have used this approach to deliver antiviral agents, liposomes, and even genes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pincus, S. H. and Tolstikov, V. V. (1995) Anti-human immunodeficiency virus immunoconjugates. Adv. Pharmacol. 32, 205ā242.
Tung, J. S., Yoshiki, T., and Fleissner, E. (1976) A core polyprotein of murine leukemia virus on the surface of mouse leukemia cells. Cell 9, 573ā578.
Pincus, S. H., Cole, R., Ireland, R., MacAtee, F., Fujisawa, R., and Portis, J. (1995) Protective efficacy of non-neutralizing monoclonal antibodies in acute infection with murine leukemia virus. J. Virol. 69, 7152ā7158.
Shang, F., Huang, H., Revesz, K., Chen, H.-C., Herz, R., and Pinter, A. (1991) Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein p17: identification of epitopes exposed at the surfaces of infected cells. J. Virol. 65, 4798ā4804.
Laurent, A. G., Krust, B., Rey, M.-A., Montagnier, L., and Hovanessian, A. G. (1989) Cell surface expression of several species of human immunodeficiency virus type 1 major core protein. J. Virol. 63, 4074ā4078.
Papsidero, L._D., Sheu, M., and Ruscetti, F. W. (1989) HIV-1 neutralizing monoclonal antibodies that react with the p17 core protein: characterization and epitope mapping. J. Virol. 63, 267ā272.
Pincus, S. H., Wehrly, K., Cole, R., Fang, H., Lewis, G. K., McClure, J., Conley, A. J., Wahren, B., Posner, M. R., Notkins, A. L., Tilley, S. A., Pinter, A., Eiden, L., Teintze, M., Dorward, D., and Tolstikov, V. V. (1996) In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on the HIV-1 envelope gly-coprotein gp160. AIDS Res. Hum. Retrovirus 12, 1041ā1051.
Till, M. A., Zolla-Pazner, S., Gorny, M. K., Patton, J. S., Uhr, J. W., and Vitetta, E. S. (1989) Human immunodeficiency virus-infected T cells and rnonocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. Proc. Natl. Acad. Sci. USA 86, 1987ā1991.
Pincus, S. H., Cole, R. L., Hersh, E. M., Lake, D., Masulho, Y., Durda, P. J., and McClure, J. (1991) In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein. J. Immunol. 146, 4315ā4324.
Pincus, S. H. and McClure, J. (1993) Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 90, 332ā336.
Kim, Y.-W., Fung, M. S. C., Sun, N.-C., Sun, C. R. Y., Chang, N. T., and Chang, T. W. (1990) Immunoconjugates that neutralize HIV virions kill T cells inferted with diverse strains of HIV-1. J. Immunol. 144, 1257ā1262.
May, R. Finkelman, F. D., Wheeler, H. T., Uhr, J. W., and Vitetta, E. S. (1990) Evaluation of ricin A chain-containing immunotoxins directed against different epitopes on the delta-chain of cell surface-associated igD on murine B cells. J. Immunol. 144, 3637ā3642.
Moore, J. P., McKeating, J. A., Huang, Y., Ashkenazi, A., and Ho, D. D. (1992) Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J. Virol. 66, 235ā243.
Clapham, P. R., Weber, J. N., Whitby, D., Mcintosh, K., Dalgleish, A. G., Maddon, P. J., Deen, K. C., Sweet, R. W., and Weiss, R. A. (1989) Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brarin and muscle cells. Nature 337, 368ā370.
Capon, D. J., Chamow, S. M., Mordenti, J., Marsters, S. A., Gregory, T., Mitsuya, H., Byrn, R. A., Lucas, C., Wurm, F. M., Groopman, J. E., Broder, S., and Smith, D. H. (1989) Designing CD4 immunoadhesins for AIDS therapy. Nature 337, 525ā531.
Traunecker, A., Schneider, J., Kieler, H., and Karjalainen, K. (1989) Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. Nature 339, 68ā70.
Davey, R. T., Boenning, C. M., Herpin, B. R., Batts, D. H., Metcalf, J. A., Wathen, L., Cox, S. R., Polis, M. A., Kovacs, J. A., Falloon, J., Walker, R. E., Salzrnan, N., Masur, H., and Lane, H. C. (1994) Recombinant soluble CD4-pseudomonas exo-toxin, a novel immunotoxin, in the treatment of individuals infected with HIV. J. Infect. Dis. 170, 1180ā1188.
Ashorn, P., Englund, G., Martin, M. A., Moss, B., and Berger, E. A. (1991) Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages. J. Infect. Dis. 163, 703ā709.
Ashorn, P., Moss, B., and Berger, E. A. (1992) Activity of CD4-Pseudomonas exotoxin against cells expressing diverse forms of the HIV and SIV envelope glycoproteins. J. AIDS 5, 70ā77.
Berger, E. A., Chaudhary, V. K., Clouse, K. A., Jaraquemada, D., Nicholas, J. A., and Rubino, K. L. (1990) Recombinant CD4-Pseudomonas exotoxin hybrid protein displays HIV-specific cytotoxicity without affecting MHC class 11-dependent functions. AIDS Res. Hum. Retroviruses 6, 795ā804.
Winters, M. A. and Merigan, T. C. (1993) Continuous presence of CD4-PE40 is required for antiviral activity against single passage HIV isolates and infected peripheral blood mononuclear cells. AIDS Res. Hum. Retroviruses 9, 1091ā1096.
Zverev, V., Sidorov, A., Zdanovsky, A., Malushova, V., Zdanovska, N., Shukhmina, N., Anjaparidze, O., Pille, E., and Melnikova, N. (1992) Inhibition of the infectivity of HIV by different forms of CD4-diphtheria recombinant immunotoxins. VIII International Conference on AIDS, Amsterdam, The Netherlands, p. 45.
Kennedy, P. E., Moss, B., and Berger, E. A. (1993) Primary HIV-1 refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin. Virology 192, 375ā379.
Aullo, P., Alcami, J., Popoff, M. R., Klatzmann, D. R., Murphy, J. R., and Boquet, P. (1992) A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV infected cells which express gp120 but selects fusion toxin resistant cells which carry HIV. EMBO J. 11, 575ā583.
Till, M. A., Ghetie, V., Gregory, T., Patzer, E. J., Porter, J. P., Uhr, J. W., Capon, D. J., and Vitetta, E. S. (1988) HIV-infected cells are killed by rCD4-ricin A chain. Science 242, 1166ā1168.
Chaudhary, V. K., Mizukami, T., Fuerst, T. R., FitzGerald, D. J., Moss, B., Pastan, I., and Berger, E. A. (1988) Selective killing of HIV-infected cells by recombinant human CD4 Pseudomonas exotoxin hybrid protein. Nature 335, 369ā372.
Berger, E. A., Clouse, K. A., Chaudhary, V. K., Chakrabarti, S., FitzGerald, D. J., Pastan, I., and Moss, B. (1989) CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immu-nodeficiency retroviruses. Proc. Natl. Acad. Sci. USA 86, 9539ā9543.
Ramachandran, R. V., Katzensteln, D. A., Wood, R., Batts, D. H., and Merigan, T. C. (1994) Failure of short-term CD4-PE40 infusions to reduce viral load in HIV infected individuals. J. Infect. Dis. 170, 1009ā1013.
Allaway, G. P., Davis-Bruno, K. L., Beaudry, G. A., Garcia, E. B., Wong, E. L., Ryder, A. M., Hasel, K. W., Gauduin, M.-C., Koup, R. A., McDougal, S., and Maddon, P. J. (1995) Expression and characterization of CD4-IgG2, a novel heteroteramer that neutralizes primary HIV-1 isolates. AIDS Res. Hum. Retroviruses 11, 533ā539.
Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M., and Berger, E. A. (1996) CC CKR5: a RANTES, MIP-1 receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955ā1958.
Feng. Y., Broder, C. C., Kennedy, P. E., and Berger, E. A. (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven transmembrane G protein-coupled receptor. Science 272, 872ā877.
Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P. D., Wu, L., Mackay, C. R., LaRosa, G., Newman, W., Gerard, N., Gerard, C., and Sodroski, J. (1996) The B-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85, 1135ā1148.
Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., and Paxton, W. A. (1996) HIV-1 entry into CD4+cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667ā673.
Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhimann, H., Koup, R. A., and Landau, N. R. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multi-ply-exposed individuals to HIV-1 infection. Cell 86, 367ā377.
Ramilo, O., Bell, K. D., Uhr, J. W., and Vitetta, E. S. (1993) Role of CD25+and CD25-T cells in acute HIV infection in vitro. J. Immunol. 150, 5202ā5208.
Finberg, R. W., Wahl, S. M., Allen, J. B., Soman, G., Strom, T. B., Murphy, J. R., and Nichols, J. C. (1991) Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin. Science 252, 1703ā1705.
Borvak, J., Chou, C.-S., Bell, K., Van Dyke, G., Zola, H., Ramilio, O., and Vitetta, E. S. (1995) Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection. J. Immunol. 155, 3196ā3204.
Borvak, J., Chou, C. S., Van Dyke, G., Rosenwirth, B., Vitetta, E. S., and Ramilo, O. (1996) The use of cyclosporine, FK506, and SDZ NIM811 to prevent CD25-quiescent peripheral blood mononuclear cells from producing human immunodeficiency virus. J. Infect. Dis. 174, 850ā853.
Bell, K. D., Ramilo, O., and Vitetta, E. S. (1993) Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 90, 1411ā1415.
Zhang, L. J., Waters, C. A., Poisson, L. R., Estis, L. F., and Crumpacker, C. S. (1997) The interleukin-2 fusion protein, DAB(389)1L-2, inhibits the development of infectious virus in human immunodeficiency virus type 1-infected human peripheral blood mononuclear cells. J. Infect. Dis. 175, 790ā794.
Renneisen, K., Leserman, L., Matthes, E., Schroder, H. C., and Muller, W. E. (1990) Inhibition of expression of human immunodeficiency virus-1 in vitro by antibody-targeted liposomes containing antisense RNA to the env region. J. Biol. Chem. 265, 16,337ā16,342.
Zarling, J. M., Moran, P. A., Haffar, O., Sias, J., Richrnan, D. D., Spina, C. A., Myers, D. E., Kuebelbeck, V., Ledbetter, J. A., and Uckun, F. M. (1990) Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+cells by monoclonal antibodies (letter). Nature 347, 92ā95.
Erice, A., Balfour, H. H., Jr., Myers, D. E., Leske, V. L., Sannerud, K. J., Kuebelbeck, V., Irvin, J. D., and Uckun, F. M. (1993) Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweeci antiviral protein. Antimicrob. Agents Chemother. 37, 835ā338.
Rombi, G., Piu, G., Piro, S., Pautasso, M., Garau, G., and Palomba, A. (1992) MAB labelled liposomes as vehicles for AZT: choice of specific monoclonal antibodies for infected cells. VIII International Conference on AIDS, Amsterdam, The Netherlands, p. 129.
Pincus, S. H., Wehrly, K., and Chesebro, B. (1989) Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J. Immunol. 142, 3070ā3075.
Pincus, S. H. (1996) Therapeutic potential of anti-HIIV immunotoxins. Antiviral Res. 33, 1ā9.
Zarling, J. M., Moran, P. A., Grosmaire, L. S., McClure, J., Shriver, K., and Ledbetter, J. A. (1988) Lysis of cells infected with HIV-1 by human lymphocytes targeted with monoclonal antibody heteroconjugates. J. Immunol. 140, 2609ā2613.
Till, M. A., Ghetie, V., May, R. D., Auerbach, P. C., Zolla-Pazner, S., Gorny, M. K., Gregory, T., Uhr, J. W., and Vitetta, E. S. (1990) Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function. J. AIDS 3, 609ā614.
Matsushita, S., Koito, A., Maeda, Y., Hattori, T., and Takatsuki, K. (1990) Selective killing of HIV-infected cells by anti-gp 120 immunotoxins. AIDS Res. Hum. Retroviruses 6, 193ā203.
Lo, K. M. S., Biasolo, M. A., Dehni, G., Palu, G., and Haseltine, W. A. (1992) Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 190, 176ā183.
Levy-Mintz, P., Duan, L. X., Zhang, H. Z., Hu, B. C., Dornadula, G., Zhu, M. H., Kulkosky, J., Bizub-Bender, D., Skalka, A. M., and Pomerantz, R. J. (1996) Intra-cellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. J. Virol. 70, 8821ā8832.
Chen, S.-Y., Zani, C., Khouri, Y., and Marasco, W. A. (1995) Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Therapy 2, 116ā123.
Konopka, K., Harrison, G. S., Felqner, P. L., and Duzgunes, N. (1997) Cationic liposome-mediated expression of HIV-regulated luciferase and diphtheria toxin a genes in HeLa cells infected with or expressing HIV. Biochim. Biophys. Acta 1356, 185ā197.
Chu, T. H. T. and Dornburg, R. (1997) Toward highlly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies. J. Virol. 71, 720ā725.
Schnell, M. J., Johnson, J. E., Buonocore, L., and Rose, J. K. (1997) Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 90, 849ā857.
Mebatsion, T., Finke, S., Weiland, F., and Conzelmann, K. K. (1997) A CXCR4/ CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 90, 841ā847.
Kabat, D., Kozak, S. L., Wehrly, K., and Chesebro, B. (1994) Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of HIV. J. Virol. 68, 2570ā2577.
Wrin, T., Loh, T. P., Vennari, J. C., Schuitemaker, H., and Nunberg, J. H. (1995) Adaptation to persistent growth in the H9 cell line renders a primary isolate of HIV-1 sensitive to neutralization by vaccine sera. J. Virol. 63, 39ā48.
Harouse, J. M., Bhat, S., Spitalnik, S. L., Laughlin, M., Stefano, K., Silberberg, D. H., and Gonzales-Scarano, F. (1991) Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science 253, 320ā323.
Fantini, J., Cook, D. G., Nathanson, N., Spitaloik, S. L., and Gonzalez-Scarano, F. (1993) Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associateo with cell surface expression of gal-actosylceramide, a potential alternative gp120 receptor. Proc. Natl. Acad. Sci. USA 90, 2700ā2704.
Pincus, S. H. and Wehrly, K. (1990) AZT demonstrates anti-HIV-1 activity in persistently infected cell lines: implications for combination chemotherapy and immunotherapy. J. Infect. Dis. 162, 1233ā1238.
Fang, H. and Pincus, S. H. (1995) Unique insertion sequence and pattern of CD4 expression in variants selected with immunotoxins from human immunodeficiency virus type 1-infected T cells. J. Virol. 69, 75ā81.
Duensing, T. D., Fang, H., Dorward, Pincus, S. H. (1995) Processing of the envelope glycoprotein gp160 in immunotoxin-resistant cell lines chronically infected with HIV-1. J. Virol. 69, 7122ā7131.
Chesebro, B., Wehrly, K., Nishio, J., and Perryman, S. (1992) Macrophage-tropic HIV isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J. Virol. 66, 6547ā6554.
Pincus, S. H., Wehrly, K., Tschachler, E., Hayes, S. F., Buller, R. S., and Reitz, M. (1990) Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin. J. Exp. Med. 172, 745ā757.
Zimmerman, K. and Mannhalter, J. W. (1996) Technical aspects of quantitative competitive PCR. BioTechniques 21, 268ā273.
Chesebro, B. and Wehrly, K. (1988) Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J. Virol. 62, 3779ā3788.
Pincus, S. H., Wehrly, K., and Chesebro, B. (1991) Use of a focal infectivity assay for testing susceptibility of HIV to antiviral agents. BioTechniques 10, 336ā342.
Chesebro, B., Wehrly, K., Metcalf, J., and Griffin, D. E. (1991) Use of a new CD4-positive HeLa cell clone for direct quantitation of infectious human immunodeficiency virus from blood cells of AIDS patients. J. Infect. Dis. 163, 64ā70.
Pincus, S. H., Messer, K. G., Schwartz, D. H., Lewis, G. K., Graham, B. S., Blattner, W. A., and Fisher, G. (1993) Differences in the antibody response to human immunodeficiency virus 1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J. Clin. Invest. 91, 1987-1996.
Pincus, S. H., Messer, K. G., and Hu, S.-L. (1994) Effect of nonprotective vaccination on antibody response to subsequent human imrnunodeficiency virus infection. J. Clin. Invest. 93, 140ā146.
Pincus, S. H., Messer, K. G., Nara, P. L., Blattner, W. A., Colclough, G., and Reitz, M. (1994) Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers. J. Clin. Invest. 93, 2505ā2513.
Moore, J. P., McKeating, J. A., Weiss, R. A., and Sattentau, Q. J. (1990) Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250, 1139ā1142.
Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997) Core structure of gp41 from the HIV envelope glycoproteih. Cell 89, 263ā273.
Rizzuto, D. D., Wyatt, R., Hernandez-Ramos, N., Sun, Y., Kwong, P. D., Hendrickson, W. A., and Sodroski, J. (1998) A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280, 1949ā1953.
Wyatt, R., Kwong, P. D., Desjardins, E., Sweet, R. W., Robinson, J., Hendrickson, W. A., and Sodroski, J. G. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393, 705ā711.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2000 Humana Press Inc.
About this protocol
Cite this protocol
Pincus, S.H. (2000). 11 Targeting HIV-Infected Cells. In: Francis, G.E., Delgado, C. (eds) Drug Targeting. Methods in Molecular Medicineā¢, vol 25. Humana Press. https://doi.org/10.1385/1-59259-075-6:193
Download citation
DOI: https://doi.org/10.1385/1-59259-075-6:193
Publisher Name: Humana Press
Print ISBN: 978-0-89603-531-7
Online ISBN: 978-1-59259-075-9
eBook Packages: Springer Protocols